1
|
Jones NT, Wagner L, Hahn MCP, Scarlett CO, Wenthur CJ. In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin. Front Psychiatry 2024; 14:1303365. [PMID: 38264637 PMCID: PMC10804612 DOI: 10.3389/fpsyt.2023.1303365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Accepted: 11/17/2023] [Indexed: 01/25/2024] Open
Abstract
Introduction The use of the psychedelic compound psilocybin in conjunction with psychotherapy has shown promising results in the treatment of psychiatric disorders, though the underlying mechanisms supporting these effects remain unclear. Psilocybin is a Schedule I substance that is dephosphorylated in vivo to form an active metabolite, psilocin. Psilacetin, also known as O-acetylpsilocin or 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT), is an unscheduled compound that has long been suggested as an alternative psilocin prodrug, though direct in vivo support for this hypothesis has thus far been lacking. Methods This study employed liquid chromatography-tandem mass spectrometry (LC-MS/MS) to assess the time-course and plasma concentrations of psilocin following the intraperitoneal (IP) administration of psilacetin fumarate or psilocybin to male and female C57Bl6/J mice. Results Direct comparisons of the time courses for psilocin exposure arising from psilocybin and psilacetin found that psilocybin led to 10-25% higher psilocin concentrations than psilacetin at 15-min post-injection. The half-life of psilocin remained approximately 30 min, irrespective of whether it came from psilocybin or psilacetin. Overall, the relative amount of psilocin exposure from psilacetin fumarate was found to be approximately 70% of that from psilocybin. Discussion These findings provide the first direct support for the long-standing assumption in the field that psilacetin functions as a prodrug for psilocin in vivo. In addition, these results indicate that psilacetin fumarate results in lower peripheral psilocin exposure than psilocybin when dosed on an equimolar basis. Thoughtful substitution of psilocybin with psilacetin fumarate appears to be a viable approach for conducting mechanistic psychedelic research in C57Bl6/J mice.
Collapse
Affiliation(s)
- Nathan T. Jones
- School of Pharmacy, University of Wisconsin-Madison, Madison, WI, United States
| | - Laura Wagner
- School of Pharmacy, University of Wisconsin-Madison, Madison, WI, United States
| | - Molly C. Pellitteri Hahn
- Analytical Instrumentation Center, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, United States
| | - Cameron O. Scarlett
- Analytical Instrumentation Center, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, United States
| | - Cody J. Wenthur
- School of Pharmacy, Transdisciplinary Center for Research in Psychoactive Substances, University of Wisconsin-Madison, Madison, WI, United States
| |
Collapse
|
2
|
Kozell LB, Eshleman AJ, Swanson TL, Bloom SH, Wolfrum KM, Schmachtenberg JL, Olson RJ, Janowsky A, Abbas AI. Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT) 2A Receptor (5-HT 2AR), 5-HT 2CR, 5-HT 1AR, and Serotonin Transporter. J Pharmacol Exp Ther 2023; 385:62-75. [PMID: 36669875 PMCID: PMC10029822 DOI: 10.1124/jpet.122.001454] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Revised: 01/03/2023] [Accepted: 01/10/2023] [Indexed: 01/22/2023] Open
Abstract
Novel psychoactive substances, including synthetic substituted tryptamines, represent a potential public health threat. Additionally, some substituted tryptamines are being studied under medical guidance as potential treatments of psychiatric disorders. Characterizing the basic pharmacology of substituted tryptamines will aid in understanding differences in potential for harm or therapeutic use. Using human embryonic kidney cells stably expressing 5-hydroxytryptamine (5-HT)1A, 5-HT2A, and 5-HT2C receptors (5-HT1AR, 5-HT2AR, and 5HT2CR, respectively) or the serotonin transporter (SERT), we measured affinities, potencies and efficacies of 21 substituted tryptamines. With the exception of two 4-acetoxy compounds, substituted tryptamines exhibited affinities and potencies less than one micromolar at the 5-HT2AR, the primary target for psychedelic effects. In comparison, half or more exhibited low affinities/potencies at 5-HT2CR, 5-HT1AR, and SERT. Sorting by the ratio of 5-HT2A to 5-HT2C, 5-HT1A, or SERT affinity revealed chemical determinants of selectivity. We found that although 4-substituted compounds exhibited affinities that ranged across a factor of 100, they largely exhibited high selectivity for 5-HT2ARs versus 5-HT1ARs and 5-HT2CRs. 5-substituted compounds exhibited high affinities for 5-HT1ARs, low affinities for 5-HT2CRs, and a range of affinities for 5-HT2ARs, resulting in selectivity for 5-HT2ARs versus 5-HT2CRs but not versus 5-HT1ARs. Additionally, a number of psychedelics bound to SERT, with non-ring-substituted tryptamines most consistently exhibiting binding. Interestingly, substituted tryptamines and known psychedelic standards exhibited a broad range of efficacies, which were lower as a class at 5-HT2ARs compared with 5-HT2CRs and 5-HT1ARs. Conversely, coupling efficiency/amplification ratio was highest at 5-HT2ARs in comparison with 5-HT2CRs and 5-HT1ARs. SIGNIFICANCE STATEMENT: Synthetic substituted tryptamines represent both potential public health threats and potential treatments of psychiatric disorders. The substituted tryptamines tested differed in affinities, potencies, and efficacies at 5-hydroxytryptamine (5-HT)2A, 5-HT2C, and 5HT1A receptors and the serotonin transporter (SERT). Several compounds were highly selective for and coupled very efficiently downstream of 5-HT2A versus 5-HT1A and 5-HT2C receptors, and some bound SERT. This basic pharmacology of substituted tryptamines helps us understand the pharmacologic basis of their potential for harm and as therapeutic agents.
Collapse
Affiliation(s)
- Laura B Kozell
- Veterans Affairs Portland Health Care System (L.B.K., A.J.E., T.L.S., S.H.B., K.M.W., J.L.S., A.J., A.I.A.) and Departments of Psychiatry (L.B.K., A.J.E., T.L.S., A.J., A.I.A.) and Behavioral Neuroscience (L.B.K., R.J.O., A.I.A.), Oregon Health & Science University, Portland, Oregon
| | - Amy J Eshleman
- Veterans Affairs Portland Health Care System (L.B.K., A.J.E., T.L.S., S.H.B., K.M.W., J.L.S., A.J., A.I.A.) and Departments of Psychiatry (L.B.K., A.J.E., T.L.S., A.J., A.I.A.) and Behavioral Neuroscience (L.B.K., R.J.O., A.I.A.), Oregon Health & Science University, Portland, Oregon
| | - Tracy L Swanson
- Veterans Affairs Portland Health Care System (L.B.K., A.J.E., T.L.S., S.H.B., K.M.W., J.L.S., A.J., A.I.A.) and Departments of Psychiatry (L.B.K., A.J.E., T.L.S., A.J., A.I.A.) and Behavioral Neuroscience (L.B.K., R.J.O., A.I.A.), Oregon Health & Science University, Portland, Oregon
| | - Shelley H Bloom
- Veterans Affairs Portland Health Care System (L.B.K., A.J.E., T.L.S., S.H.B., K.M.W., J.L.S., A.J., A.I.A.) and Departments of Psychiatry (L.B.K., A.J.E., T.L.S., A.J., A.I.A.) and Behavioral Neuroscience (L.B.K., R.J.O., A.I.A.), Oregon Health & Science University, Portland, Oregon
| | - Katherine M Wolfrum
- Veterans Affairs Portland Health Care System (L.B.K., A.J.E., T.L.S., S.H.B., K.M.W., J.L.S., A.J., A.I.A.) and Departments of Psychiatry (L.B.K., A.J.E., T.L.S., A.J., A.I.A.) and Behavioral Neuroscience (L.B.K., R.J.O., A.I.A.), Oregon Health & Science University, Portland, Oregon
| | - Jennifer L Schmachtenberg
- Veterans Affairs Portland Health Care System (L.B.K., A.J.E., T.L.S., S.H.B., K.M.W., J.L.S., A.J., A.I.A.) and Departments of Psychiatry (L.B.K., A.J.E., T.L.S., A.J., A.I.A.) and Behavioral Neuroscience (L.B.K., R.J.O., A.I.A.), Oregon Health & Science University, Portland, Oregon
| | - Randall J Olson
- Veterans Affairs Portland Health Care System (L.B.K., A.J.E., T.L.S., S.H.B., K.M.W., J.L.S., A.J., A.I.A.) and Departments of Psychiatry (L.B.K., A.J.E., T.L.S., A.J., A.I.A.) and Behavioral Neuroscience (L.B.K., R.J.O., A.I.A.), Oregon Health & Science University, Portland, Oregon
| | - Aaron Janowsky
- Veterans Affairs Portland Health Care System (L.B.K., A.J.E., T.L.S., S.H.B., K.M.W., J.L.S., A.J., A.I.A.) and Departments of Psychiatry (L.B.K., A.J.E., T.L.S., A.J., A.I.A.) and Behavioral Neuroscience (L.B.K., R.J.O., A.I.A.), Oregon Health & Science University, Portland, Oregon
| | - Atheir I Abbas
- Veterans Affairs Portland Health Care System (L.B.K., A.J.E., T.L.S., S.H.B., K.M.W., J.L.S., A.J., A.I.A.) and Departments of Psychiatry (L.B.K., A.J.E., T.L.S., A.J., A.I.A.) and Behavioral Neuroscience (L.B.K., R.J.O., A.I.A.), Oregon Health & Science University, Portland, Oregon
| |
Collapse
|
3
|
Gutman O, Tenne D, Bretler U. Psilocin - The "real deal" or an extraction byproduct. J Forensic Sci 2023; 68:327-334. [PMID: 36333836 DOI: 10.1111/1556-4029.15167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2022] [Revised: 10/21/2022] [Accepted: 10/24/2022] [Indexed: 11/07/2022]
Abstract
Most illicit drug casework samples at the Israel Police National Drug Laboratory are found to be mixtures of substances. Some are a mixture of an illicit drug with fillers, and others may contain more than one illicit drug. This study was triggered by a routine gas chromatography-mass spectrometry (GC-MS) analysis of an unusual casework sample. The sample chromatogram showed a mixture of two illicit drugs, 4-acetoxy-DMT and psilocin. Considering the two substances' similar skeletal structure, the authors wondered whether the sample was indeed a mixture of the two substances, or whether perhaps 4-acetoxy-DMT was hydrolyzed to psilocin during the analysis. This study hypothesized that indeed the base used in the pre-injection sample preparation hydrolyzed the ester group on the 4-acetoxy-DMT yielding a hydroxide group. This was tested using several concentrations of ammonium hydroxide and two additional bases - pyridine (a weak base) and sodium hydroxide (a strong base). Results showed that media with a higher pH (induced by the stronger base) yielded a higher psilocin to 4-acetoxy-DMT ratio which is compatible with degradation of 4-acetoxy-DMT. This study also explored the possibility that psilocin was a byproduct of thermal decomposition of 4-acetoxy-DMT and found it thermally stable in the temperature of the GC injection port (200°C). The 4-acetoxy-DMT case demonstrates how pre-injection laboratory procedures can inadvertently modify casework samples. Caution is clearly advisable in selecting reagents and processes in general, and specifically in the case of GC-MS pre-injection procedures conducted to analyze substances like the ones in the present study.
Collapse
Affiliation(s)
- Ori Gutman
- Division of Identification and Forensic Science, National Headquarters of the Israel Police, Jerusalem, Israel
| | - Dana Tenne
- Division of Identification and Forensic Science, National Headquarters of the Israel Police, Jerusalem, Israel
| | - Uriel Bretler
- Division of Identification and Forensic Science, National Headquarters of the Israel Police, Jerusalem, Israel
| |
Collapse
|
4
|
Glatfelter GC, Pottie E, Partilla JS, Sherwood AM, Kaylo K, Pham DNK, Naeem M, Sammeta VR, DeBoer S, Golen JA, Hulley EB, Stove CP, Chadeayne AR, Manke DR, Baumann MH. Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice. ACS Pharmacol Transl Sci 2022; 5:1181-1196. [PMID: 36407948 PMCID: PMC9667540 DOI: 10.1021/acsptsci.2c00177] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Indexed: 11/06/2022]
Abstract
4-Phosphoryloxy-N,N-dimethyltryptamine (psilocybin) is a naturally occurring tertiary amine found in many mushroom species. Psilocybin is a prodrug for 4-hydroxy-N,N-dimethyltryptamine (psilocin), which induces psychedelic effects via agonist activity at the serotonin (5-HT) 2A receptor (5-HT2A). Several other 4-position ring-substituted tryptamines are present in psilocybin-containing mushrooms, including the secondary amine 4-phosphoryloxy-N-methyltryptamine (baeocystin) and the quaternary ammonium 4-phosphoryloxy-N,N,N-trimethyltryptamine (aeruginascin), but these compounds are not well studied. Here, we investigated the structure-activity relationships for psilocybin, baeocystin, and aeruginascin, as compared to their 4-acetoxy and 4-hydroxy analogues, using in vitro and in vivo methods. Broad receptor screening using radioligand binding assays in transfected cells revealed that secondary and tertiary tryptamines with either 4-acetoxy or 4-hydroxy substitutions display nanomolar affinity for most human 5-HT receptor subtypes tested, including the 5-HT2A and the serotonin 1A receptor (5-HT1A). The same compounds displayed affinity for 5-HT2A and 5-HT1A in mouse brain tissue in vitro and exhibited agonist efficacy in assays examining 5-HT2A-mediated calcium mobilization and β-arrestin 2 recruitment. In mouse experiments, only the tertiary amines psilocin, psilocybin, and 4-acetoxy-N,N-dimethyltryptamine (psilacetin) induced head twitch responses (ED50 0.11-0.29 mg/kg) indicative of psychedelic-like activity. Head twitches were blocked by 5-HT2A antagonist pretreatment, supporting 5-HT2A involvement. Both secondary and tertiary amines decreased body temperature and locomotor activity at higher doses, the effects of which were blocked by 5-HT1A antagonist pretreatment. Across all assays, the pharmacological effects of 4-acetoxy and 4-hydroxy compounds were similar, and these compounds were more potent than their 4-phosphoryloxy counterparts. Importantly, psilacetin appears to be a prodrug for psilocin that displays substantial serotonin receptor activities of its own.
Collapse
Affiliation(s)
- Grant C. Glatfelter
- Designer
Drug Research Unit, National Institute on
Drug Abuse Intramural Research Program, Baltimore, Maryland 21224, United States
| | - Eline Pottie
- Laboratory
of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical
Sciences, Ghent University, Campus Heymans, Ottergemsesteenweg
460, 9000 Ghent, Belgium
| | - John S. Partilla
- Designer
Drug Research Unit, National Institute on
Drug Abuse Intramural Research Program, Baltimore, Maryland 21224, United States
| | | | - Kristi Kaylo
- Usona
Institute, Madison, Wisconsin 53711, United States
| | - Duyen N. K. Pham
- Department
of Chemistry & Biochemistry, University
of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States
| | - Marilyn Naeem
- Department
of Chemistry & Biochemistry, University
of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States
| | - Vamshikrishna Reddy Sammeta
- Department
of Chemistry & Biochemistry, University
of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States
| | - Stacie DeBoer
- Department
of Chemistry, University of Wyoming, Laramie, Wyoming 82071, United States
| | - James A. Golen
- Department
of Chemistry & Biochemistry, University
of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States
| | - Elliott B. Hulley
- Department
of Chemistry, University of Wyoming, Laramie, Wyoming 82071, United States
| | - Christophe P. Stove
- Laboratory
of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical
Sciences, Ghent University, Campus Heymans, Ottergemsesteenweg
460, 9000 Ghent, Belgium
| | | | - David R. Manke
- Department
of Chemistry & Biochemistry, University
of Massachusetts Dartmouth, North Dartmouth, Massachusetts 02747, United States
| | - Michael H. Baumann
- Designer
Drug Research Unit, National Institute on
Drug Abuse Intramural Research Program, Baltimore, Maryland 21224, United States
| |
Collapse
|
5
|
Zhai W, Li L, Zhao J, Xiang P, Liu M, Shi Y, Dang Y. Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MS. Drug Test Anal 2022; 14:1300-1309. [PMID: 35312166 DOI: 10.1002/dta.3255] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Revised: 03/17/2022] [Accepted: 03/17/2022] [Indexed: 12/13/2022]
Abstract
4-Acetoxy-N,N-dimethyltryptamine (4-AcO-DMT, psilacetin, O-acetylpsilocin) is a synthetic tryptamine with psychedelic properties. Psilacetin may also act as precursor drug of psilocin, similar to psilocybin, but little is known about its metabolism. In this study, the phase I and phase II in vitro metabolism of 4-AcO-DMT was investigated with pooled human liver microsomes, and the reaction mixture was analyzed using liquid chromatography-quadrupole/electrostatic field orbitrap mass spectrometry. Fifteen metabolites were formed after incubation of pooled human liver microsomes with 4-AcO-DMT (12 phase I metabolites and 3 phase II metabolites). The proposed metabolite structures were based on accurate mass analysis and MS/MS fragmentation patterns. The biotransformations included hydrolysis, hydroxylation, N-demethylation, oxidation, and conjugation with glucuronic acid. The hydrolysis metabolite was the most abundant compound. For the development of new methods for the identification of 4-AcO-DMT consumption, the beta-hydroxylation metabolite of 4-AcO-DMT (M2-1) is recommended as a biomarker. The data reported in this work might be applicable to metabolic transformation of 4-AcO-DMT in vivo and also forensically helpful.
Collapse
Affiliation(s)
- Wenya Zhai
- College of Medicine and Forensics, Xi'an Jiaotong University Health Science Center, Xi'an, China.,Department of Forensic Toxicology, Shanghai Key Laboratory of Forensic Medicine, Shanghai Forensic Science Platform, Academy of Forensic Science, Shanghai, China
| | - Le Li
- Department of Forensic Toxicology, Shanghai Key Laboratory of Forensic Medicine, Shanghai Forensic Science Platform, Academy of Forensic Science, Shanghai, China
| | - Junbo Zhao
- Department of Forensic Toxicology, Shanghai Key Laboratory of Forensic Medicine, Shanghai Forensic Science Platform, Academy of Forensic Science, Shanghai, China
| | - Ping Xiang
- Department of Forensic Toxicology, Shanghai Key Laboratory of Forensic Medicine, Shanghai Forensic Science Platform, Academy of Forensic Science, Shanghai, China
| | - Mengxi Liu
- Department of Forensic Toxicology, Shanghai Key Laboratory of Forensic Medicine, Shanghai Forensic Science Platform, Academy of Forensic Science, Shanghai, China
| | - Yan Shi
- Department of Forensic Toxicology, Shanghai Key Laboratory of Forensic Medicine, Shanghai Forensic Science Platform, Academy of Forensic Science, Shanghai, China
| | - Yonghui Dang
- College of Medicine and Forensics, Xi'an Jiaotong University Health Science Center, Xi'an, China
| |
Collapse
|
6
|
Maghsoudi N, Tanguay J, Scarfone K, Rammohan I, Ziegler C, Werb D, Scheim AI. Drug checking services for people who use drugs: a systematic review. Addiction 2022; 117:532-544. [PMID: 34729849 PMCID: PMC9299873 DOI: 10.1111/add.15734] [Citation(s) in RCA: 74] [Impact Index Per Article: 37.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Accepted: 10/14/2021] [Indexed: 12/22/2022]
Abstract
BACKGROUND AND AIMS Drug checking services provide people who use drugs with chemical analysis results of their drug samples while simultaneously monitoring the unregulated drug market. We sought to identify and synthesize literature on the following domains: (a) the influence of drug checking services on the behaviour of people who use drugs; (b) monitoring of drug markets by drug checking services; and (c) outcomes related to models of drug checking services. METHODS Systematic review. A systematic literature search was conducted in MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, PsycINFO, Scopus, Web of Science and Dissertations and Theses Global. Eligible studies were peer-reviewed articles and conference abstracts or grey literature, published in any language since 1990 and including original data on the domains. We assessed risk of bias for quantitative peer-reviewed articles reporting on behaviour or models of drug checking services using National Institutes of Health tools. RESULTS We screened 2463 titles and abstracts and 156 full texts, with 90 studies meeting inclusion criteria. Most (n = 65, 72.2%) were from Europe and used cross-sectional designs (n = 79, 87.7%). Monitoring of drug markets by drug checking services (n = 63, 70%) was the most reported domain, followed by the influence of drug checking services on behaviour (n = 31, 34.4%), including intent to use, actual use and disposal of the drug, and outcomes related to models of drug checking services (n = 17, 18.9%). The most common outcome measures were detection of unexpected substances (n = 50, 55.6%), expected substances (n = 44, 48.9%), new psychoactive substances (n = 40, 44.4%) and drugs of concern (n = 32, 36.5%) by drug checking services. CONCLUSIONS Drug checking services appear to influence behavioural intentions and the behaviour of people who use drugs, particularly when results from drug checking services are unexpected or drugs of concern. Monitoring of drug markets by drug checking services is well established in Europe, and increasingly in North America. Concerns about drug contents and negative health consequences facilitate the use of drug checking services; lack of concern; trust in drug sellers; lack of accessibility of drug checking services; and legal and privacy concerns are barriers to use.
Collapse
Affiliation(s)
- Nazlee Maghsoudi
- Centre on Drug Policy Evaluation, Li Ka Shing Knowledge InstituteSt Michael's HospitalTorontoONCanada,Institute of Health Policy, Management and EvaluationUniversity of TorontoTorontoONCanada
| | - Justine Tanguay
- Munk School of Global Affairs and Public PolicyUniversity of TorontoTorontoONCanada
| | - Kristy Scarfone
- Centre on Drug Policy Evaluation, Li Ka Shing Knowledge InstituteSt Michael's HospitalTorontoONCanada,Leslie Dan Faculty of PharmacyUniversity of TorontoTorontoONCanada
| | - Indhu Rammohan
- Centre on Drug Policy Evaluation, Li Ka Shing Knowledge InstituteSt Michael's HospitalTorontoONCanada,Institute of Health Policy, Management and EvaluationUniversity of TorontoTorontoONCanada
| | | | - Dan Werb
- Centre on Drug Policy Evaluation, Li Ka Shing Knowledge InstituteSt Michael's HospitalTorontoONCanada,Institute of Health Policy, Management and EvaluationUniversity of TorontoTorontoONCanada,Division of Infectious Diseases and Global Public Health, School of MedicineUniversity of California San DiegoLa JollaCAUSA
| | - Ayden I. Scheim
- Centre on Drug Policy Evaluation, Li Ka Shing Knowledge InstituteSt Michael's HospitalTorontoONCanada,Department of Epidemiology and Biostatistics, Dornsife School of Public HealthDrexel UniversityPhiladelphiaPAUSA
| |
Collapse
|
7
|
Hirschfeld T, Smit-Rigter L, van der Gouwe D, Reiche S, Stöver H, Majić T. Safer Tripping: Serotonergic Psychedelics and Drug Checking. Submission and Detection Rates, Potential Harms, and Challenges for Drug Analysis. CURRENT ADDICTION REPORTS 2021. [DOI: 10.1007/s40429-021-00385-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Abstract
Purpose of Review
With the continuous emergence of new psychoactive substances, drug checking (DC) services are challenged by an increasingly complex drug market. Considering the resumed scientific and public interest in serotonergic psychedelics (SPs) like LSD, psilocybin, and 2C-B, we present the results of a literature search investigating the presence and proportion of SPs in DC samples.
Recent Findings
In 15 identified reports, submission and detection rates of SPs were comparably low, but increasing. Samples contained considerable amounts of adulterations or analogues, mostly novel SPs with unknown toxicological profiles and in some cases potentially life-threatening effects. The detection of SPs, however, requires advanced analysis techniques currently not available to most DC services.
Summary
Given the substantial proportion of novel SPs in DC samples and the associated risks, DC can be a valuable harm reduction and monitoring tool for SPs if analysis techniques with high sensitivity are employed.
Collapse
|
8
|
Batistic FK, Rhumorbarbe D, Lefrancois E, Tettey J, Raithelhuber M, Rossy Q, Morelato M. Analysis of Google Trends to monitor new psychoactive substance. Is there an added value? Forensic Sci Int 2021; 326:110918. [PMID: 34325112 DOI: 10.1016/j.forsciint.2021.110918] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Revised: 07/16/2021] [Accepted: 07/18/2021] [Indexed: 11/19/2022]
Abstract
The past decade has seen an increase in the development and availability of a broad category of drugs, known as new psychoactive substances (NPS). NPS are challenging for public health authorities, therefore the two major drug monitoring bodies - the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the United Nations Office on Drugs and Crime (UNODC) - have implemented the EU Early Warning System (EWS) and Early Warning Advisory (EWA), respectively. While these monitoring systems are informative, it is difficult to keep up with the constant and rapid developmental rate of NPS. The EMCDDA has recognised the need for an alternative and technologically derived early warning system. The aim of this research is to determine whether Google Trends and drug discussion forum data can be used to complement early warning systems for NPS. Forty-eight substances were used in this study and classed into groups based on their chemical structure, following the UNODC classification system. Google Trends data (time range: 2004-2019) and drug forum data (time range: 2003-2018) were extracted for each substance and visual trend profiles were created for class groups as well as individual substances. Analysis was conducted to determine when a substance first appeared on Google Trends and a drug discussion forum as well as their trends over time. This date of first appearance was then compared to the date the substance was first reported to UNODC. Of the three data sources utilised, substances were most likely to appear on Google Trends first. Amongst the different classes of NPS, discernible trends ('block', 'successive', and 'generational' trends) were observed. These trends reflect the evolution of the manufacture of substances or generations of substances that has been observed in the literature. For example, in the synthetic cannabinoids' category, a generational trend is observed that corresponds to the different generations of synthetic cannabinoids. When comparing Google Trends and Drugs-Forum directly, the order of appearance and duration of presence for substances aligns accurately for most classes. Google Trends showed the emergence, persistence, or transient nature of substances, which could direct the focus of law enforcement, health organisation and laboratory resources towards a limited number of substances. When one considers the reliance of individual information seeking on the Web as well as the prominence of NPS on the Web, it becomes clear that Google Trends and drug discussion forums could be used as a complement to current early warning systems.
Collapse
Affiliation(s)
- Frana-Katica Batistic
- Centre for Forensic Science, School of Mathematical and Physical Sciences, University of Technology Sydney, Australia.
| | - Damien Rhumorbarbe
- Ecole des Sciences Criminelles, Faculty of Law, Criminal Justice and Public Administration, University of Lausanne, Switzerland.
| | - Elodie Lefrancois
- Ecole des Sciences Criminelles, Faculty of Law, Criminal Justice and Public Administration, University of Lausanne, Switzerland.
| | - Justice Tettey
- Laboratory and Scientific Section, Division for Policy Analysis and Public Affairs, United Nations Office on Drugs and Crime, Vienna International Centre, Vienna, Austria.
| | - Martin Raithelhuber
- Laboratory and Scientific Section, Division for Policy Analysis and Public Affairs, United Nations Office on Drugs and Crime, Vienna International Centre, Vienna, Austria.
| | - Quentin Rossy
- Ecole des Sciences Criminelles, Faculty of Law, Criminal Justice and Public Administration, University of Lausanne, Switzerland.
| | - Marie Morelato
- Centre for Forensic Science, School of Mathematical and Physical Sciences, University of Technology Sydney, Australia.
| |
Collapse
|
9
|
Gatch MB, Hoch A, Carbonaro TM. Discriminative Stimulus Effects of Substituted Tryptamines in Rats. ACS Pharmacol Transl Sci 2020; 4:467-471. [PMID: 33860176 DOI: 10.1021/acsptsci.0c00173] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2020] [Indexed: 01/17/2023]
Abstract
Novel synthetic compounds have been available for decades as quasi-legal alternatives to controlled substances. The hallucinogen-like effects of eight novel substituted tryptamines were evaluated to determine their potential abuse liability. Male Sprague-Dawley rats were trained to discriminate 2,5-dimethoxy-4-methylamphetamine (DOM, 0.5 mg/kg, i.p., 30 min) from saline. 4-Acetoxy-N,N-diethyltryptamine (4-AcO-DET), 4-hydroxy-N-methyl-N-ethyltryptamine (4-OH-MET), 4-hydroxy-N,N-diethyltryptamine (4-OH-DET), 4-acetoxy-N-methyl-N-isopropyltryptamine (4-AcO-MiPT), 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT), 4-hydroxy-N,N-dimethyltryptamine (4-OH-DMT, psilocin), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT), and 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT) were tested for their ability to substitute for the discriminative stimulus effects of DOM. All test compounds fully substituted for DOM with potencies less than or equal to that of DOM. 4-OH-MET, 4-OH-DET, 4-OH-DMT, and 4-AcO-DMT decreased response rate at doses that fully substituted. Because the test compounds produced DOM-like discriminative stimulus effects, they may have similar abuse liability as DOM. 4-Acetoxy substituted compounds were less potent than 4-hydroxy substituted compounds, and the N,N-diisopropyl compounds were less potent than the dimethyl, diethyl, N-methyl-N-ethyl, and N-methyl-N-isopropyl compounds.
Collapse
Affiliation(s)
- Michael B Gatch
- Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas 76107, United States
| | - Adam Hoch
- Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas 76107, United States
| | - Theresa M Carbonaro
- Diversion Control Division Drug and Chemical Evaluation Section, Drug Enforcement Administration Springfield, Virginia 22152, United States
| |
Collapse
|
10
|
Goncalves R, Titier K, Latour V, Peyré A, Castaing N, Daveluy A, Molimard M. Suitability of infrared spectroscopy for drug checking in harm reduction centres. THE INTERNATIONAL JOURNAL OF DRUG POLICY 2020; 88:103037. [PMID: 33207305 DOI: 10.1016/j.drugpo.2020.103037] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Revised: 10/27/2020] [Accepted: 10/30/2020] [Indexed: 11/17/2022]
Abstract
Drug checking is a service for people who use drugs that includes product analysis and an individual interview including results feedback and harm reduction counselling. It uses different analytical methods but few studies demonstrate their value in current practice. The main objective of this work is to compare the analytical performance of IR spectroscopy to laboratory reference method in the context of drug checking in a harm reduction centre. The secondary objectives are to carry out a description of the people who use drugs requesting a product analysis, and to compare the assumed compositions of products purchased with their real compositions. During 2018, all requests for drug testing analysis were included for on-site analysis by IR spectrometry in a harm reduction center and verified by the reference method (UPLC-HRMS) at Bordeaux University Hospital Center. Socioeconomic and product data were also collected. One hundred and thirty-six samples were collected. The results obtained with IR and UPLC-HRMS were compared. IR spectrometry results did not match with reference method in 8 % (n=11) of cases, corresponding to blotters, cannabis and some psychoactive substances present in mixture or in small quantities. Among the products collected, only 5.1 % (n=7) did not correspond to the declared product, either alone or with adulterants. The IR spectrometer allows a simple and rapid detection of at least one molecule, most often the one of interest. However, it is limited to powder and tablet type matrices and is not suitable for blotters, cannabis, mixed or low content substances for which high resolution mass spectrometry remains the reference method.
Collapse
Affiliation(s)
- R Goncalves
- CHU de Bordeaux, Laboratoire de Pharmacologie et Toxicologie, Place Amélie Raba Léon, F-33076 Bordeaux, Cedex, France; Univ. Bordeaux, INSERM, BPH, U1219, 146 rue Léo Saignat 11, F-33076 Bordeaux, Cedex, France.
| | - K Titier
- CHU de Bordeaux, Laboratoire de Pharmacologie et Toxicologie, Place Amélie Raba Léon, F-33076 Bordeaux, Cedex, France
| | - V Latour
- La Case, 36 rue Saint-James, F-33000 Bordeaux, France
| | - A Peyré
- CHU de Bordeaux, Centre d'addictovigilance, Place Amélie Raba Léon, F-33076 Bordeaux, Cedex, France
| | - N Castaing
- CHU de Bordeaux, Laboratoire de Pharmacologie et Toxicologie, Place Amélie Raba Léon, F-33076 Bordeaux, Cedex, France
| | - A Daveluy
- Univ. Bordeaux, INSERM, BPH, U1219, 146 rue Léo Saignat 11, F-33076 Bordeaux, Cedex, France; CHU de Bordeaux, Centre d'addictovigilance, Place Amélie Raba Léon, F-33076 Bordeaux, Cedex, France
| | - M Molimard
- CHU de Bordeaux, Laboratoire de Pharmacologie et Toxicologie, Place Amélie Raba Léon, F-33076 Bordeaux, Cedex, France; Univ. Bordeaux, INSERM, BPH, U1219, 146 rue Léo Saignat 11, F-33076 Bordeaux, Cedex, France
| |
Collapse
|
11
|
Jones NS, Comparin JH. Interpol review of controlled substances 2016-2019. Forensic Sci Int Synerg 2020; 2:608-669. [PMID: 33385148 PMCID: PMC7770462 DOI: 10.1016/j.fsisyn.2020.01.019] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2020] [Accepted: 01/23/2020] [Indexed: 12/14/2022]
Abstract
This review paper covers the forensic-relevant literature in controlled substances from 2016 to 2019 as a part of the 19th Interpol International Forensic Science Managers Symposium. The review papers are also available at the Interpol website at: https://www.interpol.int/content/download/14458/file/Interpol%20Review%20Papers%202019.pdf.
Collapse
Affiliation(s)
- Nicole S. Jones
- RTI International, Applied Justice Research Division, Center for Forensic Sciences, 3040 E. Cornwallis Road, Research Triangle Park, NC, 22709-2194, USA
| | - Jeffrey H. Comparin
- United States Drug Enforcement Administration, Special Testing and Research Laboratory, USA
| |
Collapse
|
12
|
Palamar JJ, Acosta P. A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines. Hum Psychopharmacol 2020; 35:e2719. [PMID: 31909513 PMCID: PMC6995261 DOI: 10.1002/hup.2719] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2019] [Revised: 12/02/2019] [Accepted: 12/04/2019] [Indexed: 12/19/2022]
Abstract
OBJECTIVE The number of novel psychedelic phenethylamines and tryptamines has continued to increase, but little academic research has focused on the effects of these substances. We sought to determine and compare the subjective effects of various substances. METHODS We conducted in-depth interviews with 39 adults (75.4% male and 87.2% White) who reported experience using psychedelic phenethylamines and/or tryptamines. Participants described the effects of compounds they have used. We examined the subjective drug effects in a qualitative descriptive manner. RESULTS Participants reported on the use of 36 compounds. The majority (64.1%) reported the use of 2C series drugs, with 2C-B use being most prevalent; 38.5% reported the use of NBOMe, and 25.6% reported the use of DOx. With regard to tryptamines, 46.2% reported use, and 4-AcO-DMT was the most prevalent drug used in this class. 2C-B was often described as being more favorable than other 2C series compounds with the effects described as being comparable with MDMA and LSD. NBOMe effects were generally described in an unfavorable manner, and the effects of DOx were often described as lasting too long (12-36 hr). The effects of 4-AcO-DMT were often described as mimicking psilocybin. CONCLUSION Knowing the effects of various compounds can inform education, prevention, and harm reduction efforts regarding the use of these drugs.
Collapse
Affiliation(s)
- Joseph J. Palamar
- Department of Population HealthNew York University School of Medicine New York New York
| | - Patricia Acosta
- Department of Population HealthNew York University School of Medicine New York New York
| |
Collapse
|
13
|
Palamar JJ, Le A. Trends in DMT and other tryptamine use among young adults in the United States. Am J Addict 2018; 27:578-585. [PMID: 30260086 PMCID: PMC6182767 DOI: 10.1111/ajad.12803] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2018] [Revised: 08/02/2018] [Accepted: 08/25/2018] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND AND OBJECTIVES The popularity of tryptamines such as N,N-dimethyltryptamine (DMT) appears to be increasing in the United States (US), but epidemiologic literature on prevalence of use is scant. This paper aims to determine trends in prevalence and correlates of past-year tryptamine use among a nationally representative sample of young adults in the US. METHODS Participants in the National Survey on Drug Use and Health survey were queried about past-year use of tryptamines-specifically DMT, α-methyltryptamine (AMT), and 5-MeO-DIPT ("Foxy"). Data were examined from young adults (ages 18-25), years 2007-2014 (N = 144,787). Linear trends in prevalence of past-year tryptamine use were examined in the full sample and stratified by specific demographic and drug use characteristics. RESULTS Tryptamine use is rare, but increased from .2% in 2007/08 to .7% in 2013/14, a 273% relative increase (p < .001). While prevalence increased among all demographic groups, prevalence was substantially higher among individuals who use other drugs. In particular, between 2007/08 and 2013/14, prevalence of tryptamine use increased among past-year ecstasy users (from 2.1% to 10.0%) and LSD users (from 7.0% to 15.5%) (ps < .01). Prevalence of tryptamine use tended to be higher among lifetime and past-year users of psychedelic drugs compared to users of non-psychedelic drugs. CONCLUSION While tryptamine use is not prevalent in the general young adult population, prevalence is increasing. Users of various other drugs-particularly drugs with psychedelic effects-report higher prevalence of tryptamine use. SCIENTIFIC SIGNIFICANCE Users of other drugs can be targeted when disseminating information about tryptamines to ensure user safety. (Am J Addict 2018;27:578-585).
Collapse
Affiliation(s)
- Joseph J Palamar
- Department of Population Health, New York University Langone Medical Center, New York, New York
| | - Austin Le
- Department of Population Health, New York University Langone Medical Center, New York, New York
- New York University College of Dentistry, New York, New York
| |
Collapse
|
14
|
Akhgari M, Moradi F, Ziarati P. The Texture of Psychoactive Illicit Drugs in Iran: Adulteration with Lead and other Active Pharmaceutical Ingredients. J Psychoactive Drugs 2018; 50:451-459. [DOI: 10.1080/02791072.2018.1508791] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- Maryam Akhgari
- Forensic Toxicology Department, Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
| | - Fatemeh Moradi
- Department of Toxicology and Pharmacology, Faculty of Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
| | - Parisa Ziarati
- Department of Medicinal Chemistry, Faculty of Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
| |
Collapse
|
15
|
Akhgari M, Moradi F, Ziarati P. The Texture of Psychoactive Illicit Drugs in Iran: Adulteration with Lead and other Active Pharmaceutical Ingredients. J Psychoactive Drugs 2018. [DOI: https://doi.org/10.1080/02791072.2018.1508791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Maryam Akhgari
- Forensic Toxicology Department, Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
| | - Fatemeh Moradi
- Department of Toxicology and Pharmacology, Faculty of Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
| | - Parisa Ziarati
- Department of Medicinal Chemistry, Faculty of Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
| |
Collapse
|
16
|
Wang Z, Cui H, Sun Z, Roch LM, Goldner AN, Nour HF, Sue ACH, Baldridge KK, Olson MA. Melatonin-directed micellization: a case for tryptophan metabolites and their classical bioisosteres as templates for the self-assembly of bipyridinium-based supramolecular amphiphiles in water. SOFT MATTER 2018; 14:2893-2905. [PMID: 29589034 DOI: 10.1039/c8sm00136g] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
The bulk solution properties of amphiphilic formulations are derivative of their self-assembly into higher ordered supramolecular assemblies known as micelles and of their ordering at the air-water interface. Exerting control over the surface-active properties of amphiphiles and their propensity to aggregate in pure water is most often fine-tuned by covalent modification of their molecular structure. Nevertheless structural constraints which limit the performance of amphiphiles do emerge when trying to develop more sophisticated systems which undergo for example, shape-defined controlled assembly and/or respond to external stimuli. In this regard, the template-modulated assembly of the so-called "supramolecular amphiphiles" continues to make progress ordering molecules that otherwise have very little to no driving force to aggregate in a prescribed manner in aqueous solutions. Herein we describe the template-modulated micellization and ordering at the air-water interface of bipyridinium-based supramolecular amphiphiles triggered by host-guest interactions with high specificity for the neurotransmitter melatonin over its biosynthetic synthon l-tryptophan and the thermodynamic parameters governing the template-modulated micellization process. When bound to the bipyridinium units of micellized surfactant molecules, melatonin effectively serves as "molecular glue" capable of lowering the CMC by 52% as compared to untemplated solutions. Analysis of this system suggests that a hallmark of donor-acceptor template-modulated micellization in water is a strong positively correlated temperature dependence of the CMC and the absence of a U-shaped CMC-temperature curve. Our findings make a case for the incorporation of l-tryptophan-based metabolites and their classical synthetic pharmaceutical bioisosteres as potential targets/components of donor-acceptor CT-based supramolecular amphiphile systems/materials operating in water.
Collapse
Affiliation(s)
- Zhenzhen Wang
- Health Sciences Platform, Tianjin University, Building 24, Tianjin 300072, China.
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Papaseit E, Farré M, Pérez-Mañá C, Torrens M, Ventura M, Pujadas M, de la Torre R, González D. Acute Pharmacological Effects of 2C-B in Humans: An Observational Study. Front Pharmacol 2018; 9:206. [PMID: 29593537 PMCID: PMC5859368 DOI: 10.3389/fphar.2018.00206] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Accepted: 02/23/2018] [Indexed: 12/31/2022] Open
Abstract
2,5-dimethoxy-4-bromophenethylamine (2C-B) is a psychedelic phenylethylamine derivative, structurally similar to mescaline. It is a serotonin 5-hydroxytryptamine-2A (5-HT2A), 5-hydroxytryptamine-2B (5-HT2B), and 5-hydroxytryptamine-2C (5-HT2C) receptor partial agonist used recreationally as a new psychoactive substance. It has been reported that 2C-B induces mild psychedelic effects, although its acute pharmacological effects and pharmacokinetics have not yet been fully studied in humans. An observational study was conducted to assess the acute subjective and physiological effects, as well as pharmacokinetics of 2C-B. Sixteen healthy, experienced drug users self-administered an oral dose of 2C-B (10, 15, or 20 mg). Vital signs (blood pressure and heart rate) were measured at baseline 1, 2, 3, 4, and 6 hours (h). Each participant completed subjective effects using three rating scales: the visual analog scale (VAS), the Addiction Research Centre Inventory (ARCI), and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) at baseline, 2–3 and 6 h after self-administration (maximum effects along 6 h), and the Hallucinogenic Rating Scale (maximum effects along 6 h). Oral fluid (saliva) was collected to assess 2C-B and cortisol concentrations during 24 h. Acute administration of 2C-B increased blood pressure and heart rate. Scores of scales related to euphoria increased (high, liking, and stimulated), and changes in perceptions (distances, colors, shapes, and lights) and different body feelings/surrounding were produced. Mild hallucinating effects were described in five subjects. Maximum concentrations of 2C-B and cortisol were reached at 1 and 3 h after self-administration, respectively. Oral 2C-B at recreational doses induces a constellation of psychedelic/psychostimulant-like effects similar to those associated with serotonin-acting drugs.
Collapse
Affiliation(s)
- Esther Papaseit
- Clinical Pharmacology Unit, Germans Trias i Pujol University Hospital, Institute for Health Science Research Germans Trias i Pujol, Badalona, Spain.,Department of Pharmacology, Therapeutics and Toxicology and Department of Psychiatry and Forensic Medicine, Autonomous University of Barcelona, Barcelona, Spain
| | - Magí Farré
- Clinical Pharmacology Unit, Germans Trias i Pujol University Hospital, Institute for Health Science Research Germans Trias i Pujol, Badalona, Spain.,Department of Pharmacology, Therapeutics and Toxicology and Department of Psychiatry and Forensic Medicine, Autonomous University of Barcelona, Barcelona, Spain
| | - Clara Pérez-Mañá
- Clinical Pharmacology Unit, Germans Trias i Pujol University Hospital, Institute for Health Science Research Germans Trias i Pujol, Badalona, Spain.,Department of Pharmacology, Therapeutics and Toxicology and Department of Psychiatry and Forensic Medicine, Autonomous University of Barcelona, Barcelona, Spain
| | - Marta Torrens
- Department of Pharmacology, Therapeutics and Toxicology and Department of Psychiatry and Forensic Medicine, Autonomous University of Barcelona, Barcelona, Spain.,Drug Addiction Program, Institute of Neuropsychiatry and Addictions, Barcelona, Spain
| | - Mireia Ventura
- Energy Control, Associació Benestar i Desenvolupament, Barcelona, Spain
| | - Mitona Pujadas
- Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain
| | - Rafael de la Torre
- Integrative Pharmacology and Systems Neuroscience Research Group, Neurosciences Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain.,Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain
| | - Débora González
- Department of Pharmacology, Therapeutics and Toxicology and Department of Psychiatry and Forensic Medicine, Autonomous University of Barcelona, Barcelona, Spain
| |
Collapse
|